Brind.

Mayo Clinic Study Validates Efficacy of GRAIL Multi-Cancer Early Detection Test

1 report, 1 independent Updated Thu 00:00

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A study led by researchers at Mayo Clinic evaluated the efficacy of the Galleri blood test, developed by GRAIL. The PATHFINDER 2 trial involved 32,007 participants and found cases of lung, breast, colon, and other cancers. The results were published in *Nature Medicine* and presented to an advisory panel of the Food and Drug Administration.

From wyomingnews.com

Why it matters

Some supportBrind's analysis of the reports

The advisory panel voted 7-2 that the benefits of the test outweigh its risks. However, the panel stressed that the test should augment existing recommended screenings and that a negative result does not guarantee freedom from cancer risks.

From wyomingnews.com

Who's involved

GRAILDeveloper of the Galleri multi-cancer early detection test
Mayo ClinicConducted the research and led the study on the test
FDAReceived the data and voted on the advisory panel review

Keep exploring

The entities involved

GRAIL
American biotechnology and pharmaceutical company
- A lawsuit was filed against GRAIL in the Northern District of California.Mon 01:43
- A lawsuit was filed in New York City involving the company GRAIL.Sun 23:51
Mayo Clinic
medical practice and medical research group based in Rochester, Minnesota, United States
- Mayo Clinic researchers presented findings at the ASTRO meeting in Boston.Sat 00:34
- Healthcare architecture is rapidly changing, with robotic procedures underway in Riyadh involving major players like Johnson & Johnson, Mayo Clinic, and Cleveland Clinic.Sat 00:14

Related events

Coverage

Newest first; wire copies grouped

Thu 00:00wyomingnews.com